Selected research
Industry Research
Alzheimer’s Therapeutic Industry Research Report 2026
Market perspective
The global Alzheimer’s Therapeutic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Alzheimer’s Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Alzheimer’s Therapeutic is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Alzheimer’s Therapeutic is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Alzheimer’s Therapeutic include Takeda Pharmaceutical Company Ltd, Merck & Co, F. Hoffman Le Roche, Eli Lilly, Inc, Pfizer Inc, Novartis International AG, H. Lundbeck A/S, Biotie Therapies and Axovant Sciences Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Alzheimer’s Therapeutic market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Alzheimer’s Therapeutic Market by Company
Takeda Pharmaceutical Company Ltd
Merck & Co
F. Hoffman Le Roche
Eli Lilly, Inc
Pfizer Inc
Novartis International AG
H. Lundbeck A/S
Biotie Therapies
Axovant Sciences Ltd
Astra Zeneca plc
Acadia Pharmaceuticals, Inc
Alzheimer’s Therapeutic Segment by Type
Rivastigmine
Galantamine Hydrobromide
Donepezil Hydrochloride
Memantine Hydrochloride
Alzheimer’s Therapeutic Segment by Application
Hospitals
Clinic
Other
Alzheimer’s Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alzheimer’s Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alzheimer’s Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alzheimer’s Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Alzheimer’s Therapeutic manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Alzheimer’s Therapeutic by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Alzheimer’s Therapeutic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rivastigmine
- Galantamine Hydrobromide
- Donepezil Hydrochloride
- Memantine Hydrochloride
Applications
- Hospitals
- Clinic
- Other
Companies covered
- Takeda Pharmaceutical Company Ltd
- Merck & Co
- F. Hoffman Le Roche
- Eli Lilly, Inc
- Pfizer Inc
- Novartis International AG
- H. Lundbeck A/S
- Biotie Therapies
- Axovant Sciences Ltd
- Astra Zeneca plc
- Acadia Pharmaceuticals, Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Alzheimer’s Therapeutic Market Size (2021-2032)
- 2.2.2 Global Alzheimer’s Therapeutic Sales (2021-2032)
- 2.2.3 Global Alzheimer’s Therapeutic Market Average Price (2021-2032)
- 2.3 Alzheimer’s Therapeutic by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rivastigmine
- 2.3.3 Galantamine Hydrobromide
- 2.3.4 Donepezil Hydrochloride
- 2.3.5 Memantine Hydrochloride
- 2.4 Alzheimer’s Therapeutic by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Alzheimer’s Therapeutic Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Alzheimer’s Therapeutic Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Alzheimer’s Therapeutic Revenue of Manufacturers (2021-2026)
- 3.4 Global Alzheimer’s Therapeutic Average Price by Manufacturers (2021-2026)
- 3.5 Global Alzheimer’s Therapeutic Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Alzheimer’s Therapeutic, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Alzheimer’s Therapeutic, Product Type & Application
- 3.8 Global Manufacturers of Alzheimer’s Therapeutic, Established Date
- 3.9 Global Alzheimer’s Therapeutic Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceutical Company Ltd
- 4.1.1 Takeda Pharmaceutical Company Ltd Company Information
- 4.1.2 Takeda Pharmaceutical Company Ltd Business Overview
- 4.1.3 Takeda Pharmaceutical Company Ltd Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceutical Company Ltd Alzheimer’s Therapeutic Product Portfolio
- 4.1.5 Takeda Pharmaceutical Company Ltd Recent Developments
- 4.2 Merck & Co
- 4.2.1 Merck & Co Company Information
- 4.2.2 Merck & Co Business Overview
- 4.2.3 Merck & Co Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co Alzheimer’s Therapeutic Product Portfolio
- 4.2.5 Merck & Co Recent Developments
- 4.3 F. Hoffman Le Roche
- 4.3.1 F. Hoffman Le Roche Company Information
- 4.3.2 F. Hoffman Le Roche Business Overview
- 4.3.3 F. Hoffman Le Roche Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 F. Hoffman Le Roche Alzheimer’s Therapeutic Product Portfolio
- 4.3.5 F. Hoffman Le Roche Recent Developments
- 4.4 Eli Lilly, Inc
- 4.4.1 Eli Lilly, Inc Company Information
- 4.4.2 Eli Lilly, Inc Business Overview
- 4.4.3 Eli Lilly, Inc Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Eli Lilly, Inc Alzheimer’s Therapeutic Product Portfolio
- 4.4.5 Eli Lilly, Inc Recent Developments
- 4.5 Pfizer Inc
- 4.5.1 Pfizer Inc Company Information
- 4.5.2 Pfizer Inc Business Overview
- 4.5.3 Pfizer Inc Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Inc Alzheimer’s Therapeutic Product Portfolio
- 4.5.5 Pfizer Inc Recent Developments
- 4.6 Novartis International AG
- 4.6.1 Novartis International AG Company Information
- 4.6.2 Novartis International AG Business Overview
- 4.6.3 Novartis International AG Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis International AG Alzheimer’s Therapeutic Product Portfolio
- 4.6.5 Novartis International AG Recent Developments
- 4.7 H. Lundbeck A/S
- 4.7.1 H. Lundbeck A/S Company Information
- 4.7.2 H. Lundbeck A/S Business Overview
- 4.7.3 H. Lundbeck A/S Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 H. Lundbeck A/S Alzheimer’s Therapeutic Product Portfolio
- 4.7.5 H. Lundbeck A/S Recent Developments
- 4.8 Biotie Therapies
- 4.8.1 Biotie Therapies Company Information
- 4.8.2 Biotie Therapies Business Overview
- 4.8.3 Biotie Therapies Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Biotie Therapies Alzheimer’s Therapeutic Product Portfolio
- 4.8.5 Biotie Therapies Recent Developments
- 4.9 Axovant Sciences Ltd
- 4.9.1 Axovant Sciences Ltd Company Information
- 4.9.2 Axovant Sciences Ltd Business Overview
- 4.9.3 Axovant Sciences Ltd Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Axovant Sciences Ltd Alzheimer’s Therapeutic Product Portfolio
- 4.9.5 Axovant Sciences Ltd Recent Developments
- 4.10 Astra Zeneca plc
- 4.10.1 Astra Zeneca plc Company Information
- 4.10.2 Astra Zeneca plc Business Overview
- 4.10.3 Astra Zeneca plc Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Astra Zeneca plc Alzheimer’s Therapeutic Product Portfolio
- 4.10.5 Astra Zeneca plc Recent Developments
- 4.11 Acadia Pharmaceuticals, Inc
- 4.11.1 Acadia Pharmaceuticals, Inc Company Information
- 4.11.2 Acadia Pharmaceuticals, Inc Business Overview
- 4.11.3 Acadia Pharmaceuticals, Inc Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Acadia Pharmaceuticals, Inc Alzheimer’s Therapeutic Product Portfolio
- 4.11.5 Acadia Pharmaceuticals, Inc Recent Developments
5 Global Alzheimer’s Therapeutic Market Scenario by Region
- 5.1 Global Alzheimer’s Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Alzheimer’s Therapeutic Sales by Region: 2021-2032
- 5.2.1 Global Alzheimer’s Therapeutic Sales by Region: 2021-2026
- 5.2.2 Global Alzheimer’s Therapeutic Sales by Region: 2027-2032
- 5.3 Global Alzheimer’s Therapeutic Revenue by Region: 2021-2032
- 5.3.1 Global Alzheimer’s Therapeutic Revenue by Region: 2021-2026
- 5.3.2 Global Alzheimer’s Therapeutic Revenue by Region: 2027-2032
- 5.4 North America Alzheimer’s Therapeutic Market Facts & Figures by Country
- 5.4.1 North America Alzheimer’s Therapeutic Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Alzheimer’s Therapeutic Sales by Country (2021-2032)
- 5.4.3 North America Alzheimer’s Therapeutic Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Alzheimer’s Therapeutic Market Facts & Figures by Country
- 5.5.1 Europe Alzheimer’s Therapeutic Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Alzheimer’s Therapeutic Sales by Country (2021-2032)
- 5.5.3 Europe Alzheimer’s Therapeutic Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Alzheimer’s Therapeutic Market Facts & Figures by Country
- 5.6.1 Asia Pacific Alzheimer’s Therapeutic Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Alzheimer’s Therapeutic Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Alzheimer’s Therapeutic Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Alzheimer’s Therapeutic Market Facts & Figures by Country
- 5.7.1 South America Alzheimer’s Therapeutic Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Alzheimer’s Therapeutic Sales by Country (2021-2032)
- 5.7.3 South America Alzheimer’s Therapeutic Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Alzheimer’s Therapeutic Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Alzheimer’s Therapeutic Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Alzheimer’s Therapeutic Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Alzheimer’s Therapeutic Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Alzheimer’s Therapeutic Sales by Type (2021-2032)
- 6.1.1 Global Alzheimer’s Therapeutic Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Alzheimer’s Therapeutic Sales Market Share by Type (2021-2032)
- 6.2 Global Alzheimer’s Therapeutic Revenue by Type (2021-2032)
- 6.2.1 Global Alzheimer’s Therapeutic Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Alzheimer’s Therapeutic Revenue Market Share by Type (2021-2032)
- 6.3 Global Alzheimer’s Therapeutic Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Alzheimer’s Therapeutic Sales by Application (2021-2032)
- 7.1.1 Global Alzheimer’s Therapeutic Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Alzheimer’s Therapeutic Sales Market Share by Application (2021-2032)
- 7.2 Global Alzheimer’s Therapeutic Revenue by Application (2021-2032)
- 7.2.1 Global Alzheimer’s Therapeutic Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Alzheimer’s Therapeutic Revenue Market Share by Application (2021-2032)
- 7.3 Global Alzheimer’s Therapeutic Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Alzheimer’s Therapeutic Value Chain Analysis
- 8.1.1 Alzheimer’s Therapeutic Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Alzheimer’s Therapeutic Production Mode & Process
- 8.2 Alzheimer’s Therapeutic Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Alzheimer’s Therapeutic Distributors
- 8.2.3 Alzheimer’s Therapeutic Customers
9 Global Alzheimer’s Therapeutic Analyzing Market Dynamics
- 9.1 Alzheimer’s Therapeutic Industry Trends
- 9.2 Alzheimer’s Therapeutic Industry Drivers
- 9.3 Alzheimer’s Therapeutic Industry Opportunities and Challenges
- 9.4 Alzheimer’s Therapeutic Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst